Telephone: +81-561-62-3311, ext. 2243; Fax: +81-561-61-1947
Translational and Clinical Research
Article first published online: 25 FEB 2013
Copyright © 2012 AlphaMed Press
Volume 31, Issue 3, pages 572–580, March 2013
How to Cite
Yamada, Y., Nakamura, S., Ito, K., Umemura, E., Hara, K., Nagasaka, T., Abe, A., Baba, S., Furuichi, Y., Izumi, Y., Klein, O. D. and Wakabayashi, T. (2013), Injectable Bone Tissue Engineering Using Expanded Mesenchymal Stem Cells. STEM CELLS, 31: 572–580. doi: 10.1002/stem.1300
Author contributions: Y.Y.: conception and design, financial support, provision of study material or patients, surgery, collection and assembly of data, data analysis and interpretation, manuscript writing, and final approval of manuscript; S.N.: collection and assembly of data, data analysis and interpretation, and manuscript writing; K.I., E.U., and K.H.: collection and assembly of data and data analysis; T.N.: data interpretation and histology work; A.A.: provision of study material and technical support; S.B., Y.F., and Y.I.: provision of animal study material and data analysis and/or interpretation; O.D.K.: data interpretation and manuscript writing; T.W.: Administrative support and final approval of manuscript.
Disclosure of potential conflicts of interest is found at the end of this article.
First published online in STEM CELLSEXPRESS December 7, 2012.
- Issue published online: 25 FEB 2013
- Article first published online: 25 FEB 2013
- Accepted manuscript online: 7 DEC 2012 05:40AM EST
- Manuscript Accepted: 16 OCT 2012
- Manuscript Revised: 4 OCT 2012
- Manuscript Received: 13 SEP 2012
- Japanese government research
- Fumiaki Miyaji, Yuji Yoshihara
- Yumiko Nakao of Japan Medical Materials (JMM). Grant Number: NIH R01 DE021420
- Tissue engineering;
- Regenerative medicine;
- Cell transplantation;
- Clinical application
Patients suffering from bone defects are often treated with autologous bone transplants, but this therapy can cause many complications. New approaches are therefore needed to improve treatment for bone defects, and stem cell therapy presents an exciting alternative approach. Although extensive evidence from basic studies using stem cells has been reported, few clinical applications using stem cells for bone tissue engineering have been developed. We investigated whether injectable tissue-engineered bone (TEB) composed of mesenchymal stem cells (MSCs) and platelet-rich plasma was able to regenerate functional bone in alveolar deficiencies. We performed these studies in animals and subsequently carried out large-scale clinical studies in patients with long-term follow-up; these showed good bone formation using minimally invasive MSC transplantation. All patients exhibited significantly improved bone volume with no side effects. Newly formed bone areas at 3 months were significantly increased over the preoperation baseline (p < .001) and reached levels equivalent to that of native bone. No significant bone resorption occurred during long-term follow-up. Injectable TEB restored masticatory function in patients. This novel clinical approach represents an effective therapeutic utilization of bone tissue engineering. STEM CELLS2013;31:572–580